Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CellSource CoTSE:4880 70 ROC (Joel Greenblatt) % is 15.96% as of Apr. 2026, which is 92% below its 10-year median of 192.36. GuruFocus rates TSE:4880 with a GF Score™ of 70/100 and a GF Value™ of 円779.78 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 1,321 Biotechnology companies, CellSource Co ranks better than 85.77% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CellSource Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2026 was 15.96%.
The historical rank and industry rank for CellSource Co's ROC (Joel Greenblatt) % or its related term are showing as below:
TSE:4880'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 6.48 Med: 192.36 Max: 539.88
Current: 14.69
During the past 9 years, CellSource Co's highest ROC (Joel Greenblatt) % was 539.88%. The lowest was 6.48%. And the median was 192.36%.
TSE:4880's ROC (Joel Greenblatt) % is ranked better than 85.77% of 1321
companies
in the Biotechnology industry
Industry Median: -296.6
vs TSE:4880: 14.69
CellSource Co's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -54.50% per year.
CellSource Co (TSE:4880) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
CellSource Co ROC (Joel Greenblatt) % Related Terms
CellSource Co ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for CellSource Co's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4880 vs VRTX, REGN, RVMD: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, CellSource Co's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSource Co ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSource Co's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where CellSource Co's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is two times the semi-annual (Apr. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 15.96% mean?
CellSource Co (TSE:4880) has a ROC (Joel Greenblatt) % of 15.96% as of Apr. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CellSource Co and its competitors. This is 92% below median its historical median of 192.36. Over the past decade, CellSource Co's ROC (Joel Greenblatt) % has ranged from 6.48 to 539.88. According to the industry distribution chart, CellSource Co ranks #188 out of 1321 companies in the Biotechnology industry, placing it in the top 14.2%.
Is CellSource Co's ROC (Joel Greenblatt) % too high?
CellSource Co's current ROC (Joel Greenblatt) % of 15.96% is 92% below median its 10-year median of 192.36. Over the past 10 years, this metric has ranged from a low of 6.48 to a high of 539.88. Based on the distribution chart, CellSource Co ranks #188 out of 1321 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CellSource Co has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellSource Co's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSource Co ranks #188 out of 1321 companies for ROC (Joel Greenblatt) %. This places CellSource Co in the top 14% of its industry — outperforming the majority of peers. Historically, CellSource Co's own ROC (Joel Greenblatt) % has ranged from 6.48 to 539.88 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CellSource Co and its competitors. CellSource Co's current ROC (Joel Greenblatt) % is 15.96%, which is 92% below median its own 10-year median of 192.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSource Co stock overvalued right now?
Based on GuruFocus' analysis, CellSource Co (TSE:4880) is currently considered Significantly Undervalued. The stock's GF Value™ is 円779.78, compared to a current price of 円314.00 — trading 59.7% below its estimated fair value. The current ROC (Joel Greenblatt) % is 15.96%, which is 92% below median its 10-year median of 192.36. CellSource Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For CellSource Co (TSE:4880), the current ROC (Joel Greenblatt) % is 15.96% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSource Co (TSE:4880) Overvalued in 2026?
Based on GuruFocus' analysis, CellSource Co stock appears to be undervalued.
The current stock price of 円314.00 is trading 59.7% below its estimated GF Value™ of 円779.78.
GuruFocus considers CellSource Co to be Significantly Undervalued.
Key valuation signals for TSE:4880:
ROC (Joel Greenblatt) %: 15.96% (92% below median its 10-year median of 192.36)
GF Value™: 円779.78 vs. price of 円314.00 (59.7% below fair value)
No single metric tells the full story. See the TSE:4880 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSource Co Ltd is engaged in contract manufacturing of fat-and blood-derived organizations and cells from medical institutions, provision of legal support to medical institutions in the regenerative medicine business. The company is also involved in sales of medical devices, and sales of own-brand cosmetics in the consumer business.
70GF Score
Get the complete analysis for TSE:4880
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4880 has been successfully added to your 
